Miura T, Ohno N, Miura N N, Shimada S, Yadomae T
Laboratory for Immunopharmacology of Microbial Products, Tokyo University of Pharmacy and Life Science, Japan.
Biol Pharm Bull. 1997 Oct;20(10):1103-7. doi: 10.1248/bpb.20.1103.
(1-->3)-beta-D-Glucans remained in the liver and spleen for long time, i.e. more than a month, without major structural changes/because there is no specific metabolic pathway for it in the body. However, biological activities, such as priming activity to LPS, triggered TNF-alpha synthesis, and antitumor activity was reduced more quickly. In this paper, we demonstrated the contribution of protein binding in inactivating beta-glucans. A particle beta-glucan preparation, zymosan, was treated with serum or plasma at 37 degrees C and their various biological activities were compared with zymosan alone. Such biological activities as antitumor activity, TNF-production, IL-6 production, complement activation and vascular permeability were significantly decreased by serum or plasma treatment. These results strongly suggested that the binding of serum or plasma protein(s) to beta-glucans would be a key step in inactivating a particle beta-glucan in the body.
（1→3）-β-D-葡聚糖在肝脏和脾脏中停留很长时间，即超过一个月，且无重大结构变化，因为体内没有针对它的特定代谢途径。然而，其生物活性，如对脂多糖的启动活性、引发肿瘤坏死因子-α合成的活性以及抗肿瘤活性，下降得更快。在本文中，我们证明了蛋白质结合在使β-葡聚糖失活过程中的作用。一种颗粒状β-葡聚糖制剂，即酵母聚糖，在37℃下用血清或血浆处理，并将其各种生物活性与单独的酵母聚糖进行比较。血清或血浆处理可使诸如抗肿瘤活性、肿瘤坏死因子产生、白细胞介素-6产生、补体激活和血管通透性等生物活性显著降低。这些结果有力地表明，血清或血浆蛋白与β-葡聚糖的结合将是使颗粒状β-葡聚糖在体内失活的关键步骤。
